ACIU241115P12500
- 0.00
- 0.000.00%
AC Immune Newsroom
AC Immune Reports Interim Results From Phase 2 Trial of ACI-7104.056
Express News | HC Wainwright & Co. Reiterates Buy on AC Immune, Maintains $16 Price Target
Promising Interim Data and Safety Profile Justify Buy Rating for AC Immune's ACI-7104.056 Vaccine Trial
Sector Update: Health Care Stocks Weaker Late Afternoon
AC Immune Stock Jumps 20% on Data for Parkinson's Disease Drug
S&P 500 Moves Lower; US Crude Oil Inventories Increase
Express News | AC Immune SA - May Initiate Part 2 of Vacsyn With up to 150 Patients
Express News | AC Immune SA - 100% of Patients Respond to ACI-7104.056
Express News | AC Immune SA - ACI-7104.056 Well Tolerated With No Clinically Relevant Safety Issues
Express News | AC Immune Reports Positive Interim Results From Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease
AC Immune Reports Positive Interim Results From Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease
AC Immune to Present at the Jefferies 2024 London Healthcare Conference
AC Immune SA Beat Analyst Profit Forecasts, And Analysts Have New Estimates
Optimistic Buy Rating on AC Immune Due to Promising Vaccine and Pipeline Developments
AC Immune Reports Q3 EPS CHF 0.05 Vs (CHF 0.18) Last Year
AC Immune | 6-K: Report of foreign private issuer (related to financial reporting)
AC Immune 3Q Rev $25.5M >ACIU
AC Immune 3Q EPS 5c >ACIU
Earnings Flash (ACIU) AC IMMUNE SA Reports Q3 Revenue $25.5M
Earnings Flash (ACIU) AC IMMUNE SA Reports Q3 EPS $0.05